In 2021, a team published a study aimed at quantifying the cardiovascular adverse effects of immune checkpoint inhibitors. They conducted a systematic review with meta-analysis of randomised clinical trials, whether published or not, which included at least one group of patients treated with one of these drugs. 48 trials were selected, corresponding to around 30 000 included patients. Depending on the trial, the average age of the patients varied from 51 to 74 years, and they were followed up for 7 to 33 months (1). Immunostimulatory immune checkpoint inhibitors are used in many types of cancer.
展开▼
